January 26, 2023 7:57am

My advice: open that portfolio envelope and think of a game of monopoly and follow RMi’s moves to recoup losses. As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect”.

Pre-open Indications: 2 Negative Indications and 6 Positive Indication

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.04% or (+13 points), S&P futures are UP +0.31% or (+12 point) and NASDAQ futures are UP +0.76% or (+90 points) early in the pre-open – so far

Futures were mixed on Thursday, January 26, 2023,

European markets advanced,

Asia-Pacific shares were mostly higher.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Last night, indexes were mixed as only the Dow advanced. The Dow closed up +9.88 points (+0.03%), the S&P closed DOWN -0.73 points (-0.02%) while the Nasdaq closed DOWN -20.91 points (-0.18%)

As of Wednesday’s close, all three (3) major averages are higher for the week, with the Nasdaq up 1.55%. The S&P and Dow have each gained 1.1%.

Economic Data docket: investors will get their first read on fourth-quarter economic growth. The GDP report will also include the quarterly PCE price index, providing a strong signal for the December PCE inflation reading on Friday morning. Also Thursday, durable goods orders, new-home sales and jobless claims are on tap.

 

Wednesday’s (1/24) … RegMed Investors’ (RMi) closing bell: “sector finishes down yet, made strides late in session. Sooner not later, it will be time to dive into sector equity purchases; in my case, getting it right is more often than most, why I shy away from IB/analyst price targets – so listen or read up!” … https://www.regmedinvestors.com/articles/12803

 

Ebb and flow:

Q1/23 – 2 holiday, 9 positive and 7 negative closes

Q4

·         December – 1 holiday, 13 negative and 8 positive closes

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indications:

Prime Medicine (PRME) closed up =$0.08 to $16.94 with a positive +$0.72 or +4.25% pre-open indication,

CRISPR Therapeutics (CRSP) closed down -$1.21 to $50.75 after Tuesday’s +$0.64 and Monday’s +$1.71 with a positive +$0.27 or +0.53% pre-open indication.

uniQure NV (QURE) closed up +$0.07 to $21.60 after Tuesday’s +$0.41 with a positive +$0.34 or +1.57% aftermarket indication,

Sage Therapeutics (SAGE) closed down -$0.53 to $44.51 with a positive +0.24 or +0.54% pre-open indication,

Solid Biosciences (SLDB) closed up +$0.05 to $7.34 after Tuesday’s -$0.06) with a positive +$0.53 or +7.29% pre-open indication,

Verve Therapeutics (VERV) closed down -$0.49 to $22.00 after Tuesday’s -$0.11, Monday’s +$1.01, Friday’s -$0.77 and last Thursday’s -$1.31 with a positive +$0.44 or +2% pre-open indication,

 

Negative Indications:

BioLife Solutions (BLFS) closed down -$0.85 to $24.15 after Tuesday’s -$0.18, Monday’s -$0.15 to $25.18, Friday’s +$0.57 and last Thursday’s -$0.11 with a negative -$0.35 or -1.45%

Ultragenyx (RARE) closed down -$0.09 to $43.40 after Tuesday’s +$0.68, Monday’s +$0.41, Friday’s +$0.90, last Thursday’s -$1.12 and the previous Wednesday’s +$0.12 with a negative -$0.87 or -2% aftermarket indication,

 

The BOTTOM LINE: I try to keep it simple and short!

The cell/gene therapy sector sold off Wednesday. The overall sector action was NOT encouraging; however, the afternoon session pushed some upside. The sector … still needs to clear their 2022 lows, but they are moving toward so-called better share pricing levels.

Q4 earnings are still in front of the sector, the reporting signals – I believe a downtrend is coming as weak earnings will surface and less than substantial guidance will prevail.

I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, mostly EARLY!

As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect”.

The cell/gene therapy sector’s investors need to understand the … cycle of distress will be with us until we see a better showing of platforms not, just me-too drug development of what I define as multiple companies chasing the same indication.

A couple of companies have become … black holes … of investor sentiment; yet, some get financing to continue the chain around investors’ necks until they recognize it could be forever with “some” of these equities.

I do NOT believe there aren't a lot of cell/gene therapy companies in position yet – UNTIL earnings (Q4) are reported – any breakout is a false hope with the inevitable downside re-occurring.

My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …

Remember, “Don't act like the market is in an uptrend until the market is actually in an uptrend”.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment,

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.